What beta blocker is noted for increasing the risk of type 2 diabetes mellitus?

Atenolol has been associated with an increased risk of developing type 2 diabetes mellitus, particularly in certain populations, such as those who are already at risk for metabolic disorders. This association can be attributed to the pharmacological effects of atenolol, which is a selective beta-1 adrenergic antagonist. Beta-blockers can interfere with the regulation of glucose metabolism and may also affect insulin sensitivity.

Research highlights that the use of atenolol and other beta-blockers is linked to metabolic side effects, including weight gain and glucose intolerance, which can contribute to the onset of type 2 diabetes. Atenolol's effects on the cardiovascular system, while beneficial for hypertensive patients, must be weighed against potential adverse metabolic outcomes. Therefore, patients on atenolol should be monitored for changes in glucose metabolism, especially if they have other risk factors for diabetes.